Image For Activity Cover
Heart Failure Risk Reduction in Diabetes - What the Practicing Endocrinologist Should Know
Course Description
The goals of this program are to improve endocrinologists’ and other clinicians’ understanding and competence in leveraging the cardioprotective effects of SGLT2 inhibitors to reduce heart failure risk in patients with type 2 diabetes.
Target Audience
This activity is intended for endocrinologists, cardiologists, internists, primary care physicians, advanced practice providers, and other healthcare professionals who care for individuals with diabetes who are at risk for heart failure.
Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the pathologic mechanisms by which diabetes can lead to the development of HF
  • Characterize HF outcomes from CVOTs of SGLT2 inhibitors in patients with T2D
  • Describe strategies to foster collaboration between endocrinologists and cardiologists to optimize care of patients with T2D and HF
Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.


Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.


Maintenance of Certification (MOC) - if eligible
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.00 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

Faculty and Disclosures

Jennifer B. Green, MD
Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke University Medical Center
Duke Clinical Research Institute
Durham, North Carolina

Mikhail Kosiborod, MD
Professor of Medicine
Kansas City School of Medicine
University of Missouri
Consulting Cardiologist Division of Cardiovascular Research
Department of Cardiology
Saint Luke's Mid America Heart Institute
Kansas City, Missouri

STATEMENT OF INDEPENDENCE

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:

  • Jennifer B. Green, MD: Consultant, AstraZeneca, Boehringer Ingelheim/Lilly, Hawthorne Effect/Omada, Novo Nordisk, Pfizer, Sanofi/Lexicon; Research Support, AstraZeneca, Boehinger Ingelheim/Lilly, Roche, Sanofi/Lexicon
  • Mikhail N. Kosiborod, MD: Consultant, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Lilly, Merck; Research Support, AstraZeneca, Bayer, Boehringer Ingelheim

The following SPC member who planned and reviewed content for this activity reported relevant financial relationships:

  • Andjela T. Drincic, MD: Advisory Board Member: Corcept Therapeutics

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

Disclosure information for presenters is included in their individual recorded presentations.

The following SPC members reported no relevant financial relationships:

  • Howard S. Blank, MD; Beret Ann Casey, MD; Lediya Cheru, MD; Marcelo Correia, MD, PhD; Angela M. Leung, MD; Kelly Lauter Roszko, MD, PhD; Virginia D. Sarapura, MD; Soleymani Taraneh, MD; Savitha Subramanian, MD

The ES and CCO staff involved in the development of this CME activity reported no relevant financial relationships.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company. Provided by the Endocrine Society in collaboration with Clinical Care Options

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable
Summary
Availability: On-Demand
Available Jun 21, 2021 to Jun 30, 2022
Cost: FREE
Credit Offered:
1 AMA PRA Category 1 Credit
1 ABIM-MOC Point
1 Participation Credit
Recommended
   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
      
   
Powered By